ozanezumab
mAbexperimental
Ozanezumab is a monoclonal antibody designed for the treatment of ALS and multiple sclerosis. — Wikipedia
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2009 (NCT00875446)
Timeline
Indications
Mechanism of action
- Reticulon-4INHIBITOR
RTN4 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOzanezumab ↗
- ChEMBLCHEMBL2108679 ↗
Also known as
- gsk1223249
- gsk1223249
- ozanezumab
- ozanezumab
- ozanezumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01753076 | Phase 2 | Dec 1, 2012 | GlaxoSmithKline |
| NCT01435993 | Phase 1 | Sep 8, 2011 | GlaxoSmithKline |
| NCT01424423 | Phase 1 | Feb 1, 2010 | GlaxoSmithKline |
| NCT00875446 | Phase 1 | May 1, 2009 | GlaxoSmithKline |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 4 | 4 | 2 | 2009 |
1 organizations
Page 1 / 1